Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2020-05-04 Regulatory Filings
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Chiesi Files Resubmission for Bronchitol with FDA 2 pages 110.2KB
Regulatory Filings Classification · 95% confidence The document is a media release dated 5 May 2020 from Pharmaxis Ltd announcing that their US licensee Chiesi Group has filed a resubmission to the FDA addressing a complete response letter related to the Bronchitol New Drug Application (NDA). The content focuses on regulatory progress, clinical study completion, and anticipated FDA review timelines. It does not contain financial statements, detailed financial performance data, or comprehensive management discussion. It is an announcement about regulatory and product development status rather than a financial report or detailed investor presentation. The document is longer than 5,000 characters but is clearly a press release about regulatory filing progress and not a report or transcript. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for regulatory announcements and compliance updates that do not fit other specific categories.
2020-05-04 English
Pharmaxis Appoints Dr Neil Graham as Director 2 pages 106.4KB
Board/Management Information Classification · 100% confidence The document is a media release dated 4 May 2020 announcing the appointment of Dr Neil Graham as a non-executive director to the Board of Pharmaxis Ltd. The content focuses exclusively on the change in the company's board composition, detailing Dr Graham's background and the company's statement welcoming him. There is no financial data, no mention of a report or financial results, and no indication of a shareholder vote or other event. This fits the definition of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2020-05-03 English
Initial Director's Interest Notice 2 pages 136.2KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3X Initial Director’s Interest Notice' and references ASX listing rule 3.19A.1 and section 205G of the Corporations Act. It details the appointment of a director and their relevant interests in securities and contracts, with no securities held or contracts disclosed. This matches the description of a Director's Dealing report, which involves reporting personal share transactions or interests by company directors. The document length is short and focused solely on director interests, not on financial results or other report types. Therefore, the appropriate classification is Director's Dealing (DIRS).
2020-05-03 English
Investor Presentation 19 pages 952.8KB
Investor Presentation Classification · 95% confidence The document is a detailed presentation about Pharmaxis, focusing on its drug development pipeline, management team, clinical trial progress, partnering deals, and financial highlights such as cash position and market opportunities. It includes forward-looking statements, product pipeline details, clinical trial phases, management bios, and key upcoming catalysts. There are no full financial statements or quarterly results, nor is it a transcript of a call or an announcement of voting results. The content is structured as a comprehensive overview aimed at investors, covering strategy, market potential, and operational updates. This matches the characteristics of an Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2020-04-30 English
Pharmaxis Quarterly Shareholder Update - March 2020 9 pages 390.9KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Shareholder Update – March 2020' and contains detailed discussion of business operations, clinical trial progress, impacts of COVID-19, drug development programs, and financial considerations such as milestone payments and cash on hand. It provides substantive financial and operational data for a quarter, including pipeline status and strategic outlook. The length is about 15,000 characters, indicating a comprehensive report rather than a brief announcement. The content aligns with a comprehensive interim or quarterly report rather than a simple earnings release or investor presentation. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q3 2020
2020-04-29 English
Appendix 4C - quarterly 5 pages 91.6KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B' and contains detailed quarterly cash flow statements, including operating, investing, and financing activities for the quarter ended 31 March 2020. It includes financial data such as receipts, payments, cash equivalents, and financing facilities. The document is over 10,000 characters, indicating it is a substantive financial report rather than a brief announcement. The content aligns with a quarterly financial report providing comprehensive financial data for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2020
2020-04-29 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.